Category: New response evaluation criteria in solid tumours: revised RECIST guideline

First Report of Erysiphe palczewskii Powdery Mildew of Siberian Pea Tree (Caragana arborescens) in Wisconsin and Quebec.

Shoots affected by powdery mildew had been collected from Siberian pea bushes in July 2009 on the University of Wisconsin-Madison campus and on the campus of Université Laval, Quebec City, Quebec. This unique shrub or small tree is occasionally planted in Wisconsin and three shrubs in a bunch that had been affected are the one examples identified on the UW-Madison campus.
In Quebec City, Siberian pea tree is extra generally used as a decorative, usually in hedges (as is the case of the affected vegetation on the Université Laval campus). In each areas, <10% of foliage was visibly affected, however incidence was better on shoots nearer to the bottom than on increased shoots. White-to-grayish mycelium was current on leaves and younger stems and generally utterly lined each higher and decrease leaf surfaces. Dark brown-to-black chasmothecia had been quite a few on leaf blades, petioles, and younger stems, however had been most plentiful on decrease surfaces of leaves.
Morphology of chasmothecia, together with appendages with distinctive terminal dichotomous branching, (1) was in line with descriptions and illustrations of the fungus Erysiphe palczewskii Jacz. (synonym Microsphaera palczewskii) (1-4) considered native to Asia, however often known as an invader of Europe the place it happens on the identical host. For a pattern from Université Laval, imply diameter of chasmothecia was 113 μm, imply appendage size was 185 μm, and barrel-shaped conidia that lacked fibrosin our bodies averaged 30 × 14 μm. Asci contained oval, yellow ascospores with imply dimensions of 20 × 12 μm.
DNA was extracted from chasmothecia, and nuclear rDNA sequences (633 nucleotides) of the Wisconsin (GenBank Accession No. GQ497277) and Quebec (GenBank Accession No. GQ497276) specimens differed by just one nucleotide. The sequences that had been obtained most intently matched GenBank sequences for Oidium spp. (98%) and Erysiphe spp. (97%). Further observations indicated that the identical pathogen affected Siberian pea bushes planted as ornamentals at a number of areas separated by ≥15 km in the metropolitan Quebec space.
This report extends the japanese identified restrict of E. palczewskii in the United States, beforehand identified from collections in Alaska (2), Washington (4), Idaho (4), North Dakota (3), and Minnesota (3). To our information, that is the primary report of this illness in Canada, and it signifies that the distribution of E. palczewskii is transcontinental.
Specimens from Madison, WI and Quebec, QC have been deposited in the U.S. National Fungus Collections (BPI 879152) and the Rene Pomerleau Herbarium of the Canadian Forest Service Laurentian Forestry Centre (QFB-22601). References: (1) U. Braun. Beih. Nova Hedwigia 89:1, 1987. (2) D. A. Glawe and G. A. Laursen. Online publication. doi:10:1094/PHP-2005-1017-01-BR. Plant Health Progress, 2005. (3) D. A. Glawe et al. Online publication. doi:10.1094/PHP-2006-0117-01-BR. Plant Health Progress, 2006. (4) C. Nischwitz and G. Newcombe. Plant Dis. 87:451, 2003.

First Report of Powdery Mildew Caused by Golovinomyces biocellatus on Peppermint in California.

In August of 2009, powdery mildew was noticed on peppermint (Mentha piperita L.) in a number of industrial fields in the Fall River Valley of japanese Shasta County, California. Plant progress was apparently diminished by the illness, however its affect on yield was unknown. White fungal progress was restricted to the adaxial surfaces, the place colonies had been skinny and effused. Heavily contaminated leaves developed a reddish tint as progress prematurely ceased. Doliform conidia ([26.6-] 29.2 [-31.7] × [13.2-] 15.6 [-16.8] μm) had been produced in chains of roughly six conidia.
Foot cells had been cylindrical ([41.3-] 55.2 [-75.0] × [11.2-] 12.0 [-12.8] μm). Immature chasmothecia had been yellowish brown and roughly 100.Zero μm in diameter with flexuous, mycelium-like appendages as much as 200 μm lengthy. All these options had been in line with these of Golovinomyces biocellatus. Asci weren’t noticed. To affirm the identification of the fungus, nuclear rDNA inside transcribed spacer (ITS) areas had been amplified by PCR with common primers ITS4 and ITS5.
The sequence (537 bp) was a precise match for a number of submissions of G. biocellatus in GenBank (e.g., Accession No. EU035602, a sequence of the fungus from mint in Australia [1]). Pathogenicity was confirmed by brushing spores from naturally contaminated leaves onto three rooted cuttings of M. piperita ‘Black Mitchum’. After the vegetation had been lined with a plastic bag for 36 h to keep up excessive humidity, they had been stored on a greenhouse bench at 23 to 28°C.
Three noninoculated vegetation, which served as controls, had been positioned in one other greenhouse in related situations. The experiment was repeated as soon as. All inoculated vegetation developed indicators of powdery mildew inside 7 days of inoculation whereas noninoculated vegetation remained illness free. The fungus on inoculated leaves was morphologically indistinguishable from the one used to inoculate the vegetation. To our information, that is the primary report of G. biocellatus on peppermint in California. References: (1) J. R. Liberato and J. H. Cunnington. Australas, Plant Dis. Notes 2:38, 2007.

Root and Crown Rot of Anthurium Caused by Calonectria ilicicola in Iran.

In the autumn of 2008, a extreme illness of Anthurium andraeanum with wilting and root and crown rot signs was noticed in a greenhouse in the Varamin space of Tehran. A species of Calonectria was remoted constantly from symptomatic tissues on 2% potato dextrose agar (PDA). The fungus produced perithecia and a Cylindrocladium anamorph when incubated on carnation leaf agar beneath near-ultraviolet mild at 25°C. Perithechia had been reddish brown, subglobose to ovoid, and 300 to 400 μm in diameter. Asci had been clavate, hyaline, 90 to 140 × 12 to 19 μm, and tapering to a protracted skinny stalk.
First Report of Erysiphe palczewskii Powdery Mildew of Siberian Pea Tree (Caragana arborescens) in Wisconsin and Quebec.
Ascospores had been fusoid, straight to barely curved, 1- (-3) septate, and (30-) 37 to 50 (-65) × (4-) 5 to six.5 (-7) μm (imply = 45 × 6 μm; n = 30). Penicillate conidiophores gave rise to stipe extensions that terminated in sphaeropedunculate vesicles (6-) 7 to 10 (-12) μm in diameter. Conidia had been hyaline, cylindrical, rounded at each ends, straight, (45-) 70 to 82 (-90) × (4-) 5 to six.5(-7) μm (imply = 62 × 6 μm; n = 30), and (1-) 3-septate. On the premise of morphology, the fungus was recognized as Calonectria ilicicola Boedijin & Reitsma.
Koch’s postulates had been fulfilled by spray inoculating 1-month-old seedlings with a conidial and mycelial suspension (105 particles per ml) of the fungus obtained from 14-day-old single-spore colonies grown on PDA at 25°C. Following inoculation, all vegetation had been maintained in plastic baggage in a glasshouse at 25 ± 1°C. After 15 to 25 days, signs resembling these seen in the diseased glasshouse had been detected on inoculated vegetation. C. ilicicola was reisolated from the artificially contaminated tissues.
No signs had been detected on the management vegetation. Nucleotide sequences of the interior transcribed spacer (ITS) areas of the nrDNA operon and the partial histone H3 gene had been decided for derived pressure CPC 16334 as described beforehand (1,3). The ITS sequence (GenBank Accession No. GU057378) matched 100% (644/644 bp) with the sequence of C. ilicicola pressure CBS 463.76 (GenBank AF493963) and the histone H3 sequence (GenBank GU057379) matched 99% (456/458 bp; as a result of two versus three AC repeats in the sequence) with that of C.

Human Neurofascin (NFASC) ELISA Kit
RD-NFASC-Hu-48Tests 48 Tests
EUR 563

Human Neurofascin (NFASC) ELISA Kit
RD-NFASC-Hu-96Tests 96 Tests
EUR 783

Neurofascin (NFASC) Antibody
20-abx214122
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Neurofascin (NFASC) Antibody
20-abx101003
  • EUR 453.00
  • EUR 133.00
  • EUR 1316.00
  • EUR 620.00
  • EUR 342.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Neurofascin (NFASC) Antibody
20-abx173762
  • EUR 926.00
  • EUR 467.00
  • 1 mg
  • 200 ug
  • Please enquire.

Neurofascin (NFASC) Antibody
20-abx241687
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Neurofascin (NFASC) Antibody
abx431852-200ul 200 ul
EUR 384
  • Shipped within 1-3 working days.

Neurofascin (NFASC) Antibody
20-abx002202
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul
  • Shipped within 5-10 working days.

Human Neurofascin (NFASC)
1-CSB-EP015743HU
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 15.9 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Human Neurofascin(NFASC),partial expressed in E.coli

Recombinant Neurofascin (NFASC)
4-RPL939Hu01
  • EUR 510.37
  • EUR 239.00
  • EUR 1638.88
  • EUR 612.96
  • EUR 1125.92
  • EUR 404.00
  • EUR 3947.20
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: O94856
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 28.3kDa
  • Isoelectric Point: Inquire
Description: Recombinant Human Neurofascin expressed in: E.coli

Human Neurofascin (NFASC) Protein
20-abx068240
  • EUR 718.00
  • EUR 286.00
  • EUR 2207.00
  • EUR 843.00
  • EUR 509.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-12 working days.

Neurofascin (NFASC) Polyclonal Antibody (Human)
4-PAL939Hu01
  • EUR 262.00
  • EUR 2747.00
  • EUR 679.00
  • EUR 331.00
  • EUR 220.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC)

Neurofascin (NFASC) Polyclonal Antibody (Human), APC
4-PAL939Hu01-APC
  • EUR 368.00
  • EUR 3599.00
  • EUR 993.00
  • EUR 472.00
  • EUR 229.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC). This antibody is labeled with APC.

Neurofascin (NFASC) Polyclonal Antibody (Human), Biotinylated
4-PAL939Hu01-Biotin
  • EUR 328.00
  • EUR 2697.00
  • EUR 786.00
  • EUR 404.00
  • EUR 226.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC). This antibody is labeled with Biotin.

Neurofascin (NFASC) Polyclonal Antibody (Human), Cy3
4-PAL939Hu01-Cy3
  • EUR 449.00
  • EUR 4757.00
  • EUR 1283.00
  • EUR 588.00
  • EUR 264.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC). This antibody is labeled with Cy3.

Neurofascin (NFASC) Polyclonal Antibody (Human), FITC
4-PAL939Hu01-FITC
  • EUR 314.00
  • EUR 2899.00
  • EUR 814.00
  • EUR 397.00
  • EUR 203.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC). This antibody is labeled with FITC.

Neurofascin (NFASC) Polyclonal Antibody (Human), HRP
4-PAL939Hu01-HRP
  • EUR 335.00
  • EUR 3135.00
  • EUR 877.00
  • EUR 426.00
  • EUR 215.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC). This antibody is labeled with HRP.

Neurofascin (NFASC) Polyclonal Antibody (Human), PE
4-PAL939Hu01-PE
  • EUR 314.00
  • EUR 2899.00
  • EUR 814.00
  • EUR 397.00
  • EUR 203.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC). This antibody is labeled with PE.

Human Neurofascin(NFASC) ELISA kit
CSB-EL015743HU-24T 1 plate of 24 wells
EUR 165
  • Sample volume: 50-100ul
  • Detection wavelength: 450nm
  • Assay performance time: 1 to 4 hours.
Description: Quantitativesandwich ELISA kit for measuring Human Neurofascin (NFASC) in samples from serum, plasma, cerebrospinalfluid (CSF), tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human Neurofascin(NFASC) ELISA kit
1-CSB-EL015743HU
  • EUR 804.00
  • EUR 5099.00
  • EUR 2704.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
  • Sample volume: 50-100ul
  • Detection wavelength: 450nm
  • Assay performance time: 1 to 4 hours.
Description: Quantitativesandwich ELISA kit for measuring Human Neurofascin(NFASC) in samples from serum, plasma, cerebrospinalfluid(CSF), tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Neurofascin (NFASC) ELISA Kit
20-abx152492
  • EUR 7378.00
  • EUR 3933.00
  • EUR 911.00
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests
  • Shipped within 5-7 working days.

Chicken Neurofascin, NFASC ELISA KIT
ELI-15003c 96 Tests
EUR 928

Human Neurofascin, NFASC ELISA KIT
ELI-20708h 96 Tests
EUR 824

Mouse Neurofascin, Nfasc ELISA KIT
ELI-45737m 96 Tests
EUR 865

Rat Neurofascin (NFASC) ELISA Kit
abx391685-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

Human Neurofascin (NFASC) CLIA Kit
20-abx495996
  • EUR 8569.00
  • EUR 4560.00
  • EUR 1052.00
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests
  • Please enquire.

Mouse Neurofascin (NFASC) ELISA Kit
abx390014-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

Human Neurofascin(NFASC)ELISA Kit
QY-E01656 96T
EUR 394

Human Neurofascin (NFASC) ELISA Kit
SEL939Hu-10x96wellstestplate 10x96-wells test plate
EUR 5189.65
  • The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Neurofascin (NFASC) were tested on 3 different plates, 8 replicates in each plate
  • CV(%) = SD/meanX100
  • Intra-Assay: CV<10%
  • Inter-Assay: CV<12%
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Neurofascin (NFASC) in Tissue homogenates and other biological fluids.

Human Neurofascin (NFASC) ELISA Kit
SEL939Hu-1x48wellstestplate 1x48-wells test plate
EUR 515.03
  • The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Neurofascin (NFASC) were tested on 3 different plates, 8 replicates in each plate
  • CV(%) = SD/meanX100
  • Intra-Assay: CV<10%
  • Inter-Assay: CV<12%
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Neurofascin (NFASC) in Tissue homogenates and other biological fluids.

Human Neurofascin (NFASC) ELISA Kit
SEL939Hu-1x96wellstestplate 1x96-wells test plate
EUR 692.9
  • The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Neurofascin (NFASC) were tested on 3 different plates, 8 replicates in each plate
  • CV(%) = SD/meanX100
  • Intra-Assay: CV<10%
  • Inter-Assay: CV<12%
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Neurofascin (NFASC) in Tissue homogenates and other biological fluids.

Human Neurofascin (NFASC) ELISA Kit
SEL939Hu-5x96wellstestplate 5x96-wells test plate
EUR 2818.05
  • The Intra-assay Precision is determined when 3 samples with low, middle and high level of Human Neurofascin (NFASC) were tested on 3 different plates, 8 replicates in each plate
  • CV(%) = SD/meanX100
  • Intra-Assay: CV<10%
  • Inter-Assay: CV<12%
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Neurofascin (NFASC) in Tissue homogenates and other biological fluids.

Human Neurofascin (NFASC) ELISA Kit
4-SEL939Hu
  • EUR 5240.00
  • EUR 2769.00
  • EUR 693.00
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
  • Known also as Neurofascin elisa. Alternative names of the recognized antigen: NF
  • NRCAML
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Neurofascin (NFASC) in samples from Tissue homogenates and other biological fluids. with no significant corss-reactivity with analogues from other species.

Neurofascin (NFASC) Polyclonal Antibody (Human), APC-Cy7
4-PAL939Hu01-APC-Cy7
  • EUR 616.00
  • EUR 7078.00
  • EUR 1867.00
  • EUR 824.00
  • EUR 338.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: NFASC (Asn760~Ala1007)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Neurofascin (NFASC). This antibody is labeled with APC-Cy7.

ELISA kit for Human NFASC (Neurofascin)
ELK6104 1 plate of 96 wells
EUR 432
  • The microtiter plate provided in this kit has been pre-coated with an antibody specific to Neurofascin (NFASC). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Neurofascin (N
  • Show more
Description: A sandwich ELISA kit for detection of Neurofascin from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Rabbit Anti- Rat neurofascin (Nfasc)-phospor IgG (aff pure)
AB-23249-A 100ug
EUR 482

Nfasc ELISA Kit| Rat Neurofascin ELISA Kit
EF019045 96 Tests
EUR 689

Nfasc ELISA Kit| Mouse Neurofascin ELISA Kit
EF015653 96 Tests
EUR 689

NFASC ELISA Kit| chicken Neurofascin ELISA Kit
EF012420 96 Tests
EUR 689

Rat neurofascin (Nfasc)-control Control/blocking peptide
AB-23249-CP 100ug
EUR 164

Rat neurofascin (Nfasc)-phosphor Control/blocking peptide
AB-23249-P 100ug
EUR 164

Recombinant Human NFASC/ Neurofascin Protein, His, E.coli-100ug
QP6416-ec-100ug 100ug
EUR 408

Recombinant Human NFASC/ Neurofascin Protein, His, E.coli-10ug
QP6416-ec-10ug 10ug
EUR 200

Recombinant Human NFASC/ Neurofascin Protein, His, E.coli-1mg
QP6416-ec-1mg 1mg
EUR 1632

Recombinant Human NFASC/ Neurofascin Protein, His, E.coli-200ug
QP6416-ec-200ug 200ug
EUR 634

Recombinant Human NFASC/ Neurofascin Protein, His, E.coli-500ug
QP6416-ec-500ug 500ug
EUR 1060

Recombinant Human NFASC/ Neurofascin Protein, His, E.coli-50ug
QP6416-ec-50ug 50ug
EUR 263

Anti-NFASC antibody
STJ24750 100 µl
EUR 277
Description: This gene encodes an L1 family immunoglobulin cell adhesion molecule with multiple IGcam and fibronectin domains. The protein functions in neurite outgrowth, neurite fasciculation, and organization of the axon initial segment (AIS) and nodes of Ranvier on axons during early development. Both the AIS and nodes of Ranvier contain high densities of voltage-gated Na+ (Nav) channels which are clustered by interactions with cytoskeletal and scaffolding proteins including this protein, gliomedin, ankyrin 3 (ankyrin-G), and betaIV spectrin. This protein links the AIS extracellular matrix to the intracellular cytoskeleton. This gene undergoes extensive alternative splicing, and the full-length nature of some variants has not been determined.

Anti-Neurofascin (aa877-890) antibody
STJ72603 100 µg
EUR 359

Rabbit Polyclonal antibody Anti-CRBN
Anti-CRBN 50 µg
EUR 349

Neurofascin
PR15066 50 ug
EUR 468

NFASC Antibody
31250-100ul 100ul
EUR 252

NFASC Antibody
31250-50ul 50ul
EUR 187

NFASC antibody
38553-100ul 100ul
EUR 252

NFASC Antibody
1-CSB-PA073153
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against NFASC. Recognizes NFASC from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100

NFASC Antibody
1-CSB-PA787178
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against NFASC. Recognizes NFASC from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

NFASC Antibody
DF7160 200ul
EUR 304
Description: NFASC Antibody detects endogenous levels of total NFASC.

NFASC Antibody
ABD7160 100 ug
EUR 438

NFASC Conjugated Antibody
C31250 100ul
EUR 397

NFASC Conjugated Antibody
C38553 100ul
EUR 397

Nfasc/ Rat Nfasc ELISA Kit
ELI-22181r 96 Tests
EUR 886

NFASC siRNA
20-abx903541
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

NFASC siRNA
20-abx925794
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

NFASC siRNA
20-abx925795
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

Polyclonal Goat anti-GST α-form
GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form
GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form
GST-ANTI-3 50 uL
EUR 280

NFASC Blocking Peptide
DF7160-BP 1mg
EUR 195

NFASC Rabbit pAb
A3053-100ul 100 ul
EUR 308

NFASC Rabbit pAb
A3053-200ul 200 ul
EUR 459

NFASC Rabbit pAb
A3053-20ul 20 ul
EUR 183

NFASC Rabbit pAb
A3053-50ul 50 ul
EUR 223

Polyclonal Neurofascin (aa877-890) Antibody (internal region)
AMM06631G 0.1 mg
EUR 484
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Neurofascin (aa877-890) (internal region). This antibody is tested and proven to work in the following applications:

NFASC ELISA KIT|Human
EF005338 96 Tests
EUR 689

Rat NFASC shRNA Plasmid
20-abx987343
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

Human NFASC shRNA Plasmid
20-abx958008
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

Mouse NFASC shRNA Plasmid
20-abx983017
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

Nfasc ORF Vector (Rat) (pORF)
ORF071257 1.0 ug DNA
EUR 506

Nfasc ORF Vector (Rat) (pORF)
ORF071258 1.0 ug DNA
EUR 506

Nfasc ORF Vector (Rat) (pORF)
ORF071259 1.0 ug DNA
EUR 506

Nfasc ORF Vector (Rat) (pORF)
ORF071260 1.0 ug DNA
EUR 506

NFASC ORF Vector (Human) (pORF)
ORF026068 1.0 ug DNA
EUR 405

Nfasc ORF Vector (Mouse) (pORF)
ORF051272 1.0 ug DNA
EUR 506

Nfasc ORF Vector (Mouse) (pORF)
ORF051273 1.0 ug DNA
EUR 506

Nfasc ORF Vector (Mouse) (pORF)
ORF051274 1.0 ug DNA
EUR 506

Nfasc ORF Vector (Mouse) (pORF)
ORF051275 1.0 ug DNA
EUR 506

NFASC ELISA Kit (Human) (OKCD01074)
OKCD01074 96 Wells
EUR 909
Description: Description of target: Cell adhesion, ankyrin-binding protein which may be involved in neurite extension, axonal guidance, synaptogenesis, myelination and neuron-glial cell interactions.By similarity ;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: < 0.115 ng/mL

Nfasc sgRNA CRISPR Lentivector set (Rat)
K7550101 3 x 1.0 ug
EUR 339

Nfasc sgRNA CRISPR Lentivector set (Mouse)
K4184901 3 x 1.0 ug
EUR 339

NFASC sgRNA CRISPR Lentivector set (Human)
K1420901 3 x 1.0 ug
EUR 339

Nfasc sgRNA CRISPR Lentivector (Rat) (Target 1)
K7550102 1.0 ug DNA
EUR 154

Nfasc sgRNA CRISPR Lentivector (Rat) (Target 2)
K7550103 1.0 ug DNA
EUR 154

Nfasc sgRNA CRISPR Lentivector (Rat) (Target 3)
K7550104 1.0 ug DNA
EUR 154

Nfasc sgRNA CRISPR Lentivector (Mouse) (Target 1)
K4184902 1.0 ug DNA
EUR 154

Nfasc sgRNA CRISPR Lentivector (Mouse) (Target 2)
K4184903 1.0 ug DNA
EUR 154

Nfasc sgRNA CRISPR Lentivector (Mouse) (Target 3)
K4184904 1.0 ug DNA
EUR 154
ilicicola pressure CBS 112217 (GenBank AY725686). To our information, that is the primary report of Calonectria and Cylindrocladium genera and the illness brought on by C. ilicicola from Iran. References: (1) R. Cheewangkoon et al. Persoonia 23:55, 2009. (2) P. W. Crous and M. J. Wingfield. Mycotaxon 51:341, 1994. (3) P. W. Crous et al. Stud. Mycol. 50:415, 2004.

Molecular data reveals a new holomorphic marine fungus, Halobyssothecium estuariae, and the asexual morph of Keissleriella phragmiticola

This examine introduces a novel holomorphic marine fungal species, Halobyssothecium estuariae (Lentitheciaceae, Pleosporales), from lifeless Phragmites communis. The new species has semi-immersed, subglobose or ellipsoidal, papillate, conical ascomata, clavate to subcylindrical, quick pedicellate asci and 3-septate, fusoid to ellipsoidal ascospores with rounded ends, pale brown to darkish brown central cells and hyaline finish cells.
The asexual morph has multiseptate, filiform, intercalary, catenate, branched chlamydospores that resemble Xylomyces. The asexual morph of Keissleriella phragmiticola based mostly on mixed LSU, SSU, ITS and TEF1 sequence analyses is reported. The function of molecular identification in delineating cryptic species are additionally mentioned.

First report of Colletotrichum fructicola inflicting anthracnose on Pouteria campechiana in China

Pouteria campechiana (Kunth) Baehni (=Lucuma nervosa A. DC.) is a fruit crop planted in southern China (Gao et al. 2019). It is initially from Central America, and additionally grown there commercially in addition to in some American states (Fadzilah et al. 2018). In March 2019, a leaf spot illness was discovered on P. campechiana in Baoshan, Yunnan, China. Field surveys have been completed in a 0.06 ha orchard in Yunnan Province. Leaf spots have been discovered on 90% of six-year-old vegetation on this subject and have been noticed in different planting areas. The signs initially appeared as small, spherical, brown spots. As the illness developed, the heart of the lesions was sunken with a darkish brown border (Fig. 1).
Under extreme situations, some spots have been joined into bigger irregular spots, and even complete leaves died. The illness severity of completely different vegetation diversified, and some leaves confirmed solely a few brown spots whereas others confirmed many spots. Small fragments of diseased tissues (3×Three mm) have been disinfected in 75% ethanol for 10 s, 1% NaClO for 1 min, and rinsed 3 times in sterilized water.
Then, tissues have been positioned onto potato dextrose agar (PDA), and incubated at 25°C in the darkish for five days. Fungal isolates with comparable morphology have been persistently recovered from diseased tissues. The 25 colonies have been initially cottony, pale white to pale grey on the higher facet and greyish-green with black zonation on the underside of plates.
Conidia have been single-celled and hyaline, aseptate, straight, and cylindrical, with rounded ends (Fig. 1B). The size and width of 200 conidia have been measured for 2 consultant isolates, DHG-1 and DHG-2, and these averaged 14.48 × 5.59 μm and 14.92 × 5.57 μm. Appressoria have been ovoid, generally clavate, brown, averaged 7.47 × 5.86 μm and 7.25 × 5.85 μm (n=30). Brown and globose ascocarp have been noticed on the leaves of Pouteria campechiana.
 Asci have been unitunicate, thin-walled, 6-Eight spored, clavate, averaged 51.53×13.01 μm and 50.21 × 13.32 μm (n=30). Ascospores have been hyaline, one-celled, barely curved to curved with obtuse to barely rounded ends, averaged 14.64×5.97 μm and 15.19 × 6.23 μm (n=30). These two isolates have been chosen for molecular identification. DNA was extracted from mycelia with the DNA safe Plant Kit (TIANGEN, Biotech, China).
For additional molecular identification, the inside transcribed spacer (ITS), partial actin (ACT), calmodulin (CAL), chitin synthase (CHS-1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-tubulin (TUB2), and the Apn2-Mat1-2 intergenic spacer and partial mating kind (Mat1-2) gene (ApMat) genes of the strains (DHG-1, DHG-2) have been amplified utilizing the primer pairs ITS1/ITS4, ACT-512F/ACT-783R, CL1C/CL2C, CHS-79F/CHS-345R, GDF1/GDR1, T1/Bt-2b, and AM-F/AM-R (Weir et al. 2012; Silva et al. 2012), respectively.
The sequences have been obtained and in contrast with GenBank and all of them confirmed over 99% id to the kind pressure of Colletotrichum fructicola ICMP 18581 (Accession nos. JX010165, JX010033, JQ807838, FJ907426, JX010405, JX009866, and FJ917508) (Weir et al. 2012). A phylogenetic tree based mostly on the mixed ITS, ACT, CAL, CHS-1, TUB2, GAPDH and ApMat sequences utilizing the Neighbor-joining algorithm revealed that the isolates have been C. fructicola (Fig. 2). The sequences have been deposited into GenBank with accession MN955541, MN955542, and MN966581 to MN966592.
Molecular data reveals a new holomorphic marine fungus, Halobyssothecium estuariae, and the asexual morph of Keissleriella phragmiticola
Pathogenicity assessments have been carried out on eighteen wholesome and tender leaves of six 1-year-old P. campechiana vegetation in a greenhouse. The experiment was repeated twice. The size and width of the inoculated leaves have been between 8-13 cm × 2.5-3.6 cm. The dermis of every examined leaf was evenly scratched in six separate areas with a sterilized needle. Each isolate was inoculated onto at the very least three wounded leaves by inserting 20 μL of a conidial suspension (106 conidia/mL) on the wound websites. Control leaves have been additionally wounded and inoculated with distilled water.
All the vegetation have been then sprayed with distilled water and lined with plastic luggage. After 10 days, preliminary signs appeared as round and deep yellow spots. After a few extra days, the spots grew to become brown, enlarged to as much as 4.Zero mm which was much like signs noticed in the subject, whereas controls remained symptomless. Koch’s postulates have been fulfilled by re-isolation of C. fructicola from diseased leaves, and identification confirmed by sequencing.
Colletotrichum fructicola has been related to anthracnose on mango, apple, pear and cassava (Oliveira et al. 2018). To our data, that is the first report of C. fructicola related to anthracnose of P. campechiana worldwide. These outcomes will present essential info for future epidemiological research and for administration of this illness.

FgPal1 regulates morphogenesis and pathogenesis in Fusarium graminearum

Ascospores are the main inoculum in Fusarium graminearum, a causal agent of wheat head blight. In a earlier examine, FgPAL1 was discovered to be up-regulated in the Fgama1 mutant and vital for ascosporogenesis. However, the organic operate of this well-conserved gene in filamentous ascomycetes isn’t clear. In this examine, we characterised its capabilities in progress, differentiation, and pathogenesis. The Fgpal1 mutant had extreme progress defects and typically displayed irregular hyphal ideas.
It was faulty in infectious progress in rachis tissues and spreading in wheat heads. The Fgpal1 mutant produced conidia with fewer septa and extra nuclei per compartment than the wild kind. In actively rising hyphal ideas, FgPal1-GFP primarily localized to the subapical collar and septa. The FgPal1 and LifeAct partially co-localized at the subapical area in the interdependent method.

Tenascin C Antibody
20-abx141185
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul
  • Shipped within 5-10 working days.

Tenascin (TN-C) Antibody
3628-100
EUR 349

Tenascin (TN-C) Antibody
3628-30T
EUR 146

Tenascin-C Polyclonal Antibody
41914-100ul 100ul
EUR 252

Tenascin-C Polyclonal Antibody
41914-50ul 50ul
EUR 187

Tenascin C (TNC) Antibody
abx219024-100ug 100 ug
EUR 439
  • Shipped within 5-10 working days.

Tenascin C (TNC) Antibody
20-abx212803
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Tenascin C (TNC) Antibody
20-abx100416
  • EUR 411.00
  • EUR 133.00
  • EUR 1149.00
  • EUR 565.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Tenascin C (TNC) Antibody
20-abx100417
  • EUR 439.00
  • EUR 133.00
  • EUR 1233.00
  • EUR 592.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Tenascin C (TNC) Antibody
20-abx100418
  • EUR 439.00
  • EUR 133.00
  • EUR 1247.00
  • EUR 592.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Tenascin C (TNC) Antibody
20-abx129349
  • EUR 425.00
  • EUR 133.00
  • EUR 1177.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Tenascin C (TNC) Antibody
20-abx130202
  • EUR 439.00
  • EUR 133.00
  • EUR 1247.00
  • EUR 592.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Tenascin C (TNC) Antibody
20-abx132091
  • EUR 328.00
  • EUR 815.00
  • EUR 425.00
  • EUR 154.00
  • EUR 258.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-7 working days.

Tenascin C Conjugated Antibody
C48835 100ul
EUR 397

Tenascin C (TNC) Antibody
20-abx327174
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin C (TNC) Antibody
abx433386-200ul 200 ul
EUR 286
  • Shipped within 1-3 working days.

Tenascin-C Polyclonal Antibody
ABP53279-003ml 0.03ml
EUR 158
  • Immunogen information: Synthesized peptide derived from the C-terminal region of human Tenascin-C
  • Applications tips:
Description: A polyclonal antibody for detection of Tenascin-C from Human, Mouse, Rat. This Tenascin-C antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Tenascin-C

Tenascin-C Polyclonal Antibody
ABP53279-01ml 0.1ml
EUR 289
  • Immunogen information: Synthesized peptide derived from the C-terminal region of human Tenascin-C
  • Applications tips:
Description: A polyclonal antibody for detection of Tenascin-C from Human, Mouse, Rat. This Tenascin-C antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Tenascin-C

Tenascin-C Polyclonal Antibody
ABP53279-02ml 0.2ml
EUR 414
  • Immunogen information: Synthesized peptide derived from the C-terminal region of human Tenascin-C
  • Applications tips:
Description: A polyclonal antibody for detection of Tenascin-C from Human, Mouse, Rat. This Tenascin-C antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Tenascin-C

Anti-Tenascin C Antibody
A1666-100
EUR 479

Tenascin-C Polyclonal Antibody
ES4278-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Tenascin-C from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

Tenascin-C Polyclonal Antibody
ES4278-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Tenascin-C from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

Anti-Tenascin-C antibody
STJ16100797 100 µg
EUR 557

Anti-Tenascin-C antibody
STJ16100798 100 µg
EUR 557

Anti-Tenascin-C antibody
STJ16101005 100 µg
EUR 354

Anti-Tenascin-C antibody
STJ97243 200 µl
EUR 197
Description: Rabbit polyclonal to Tenascin-C.

anti-Tenascin C
YF-PA23936 50 ul
EUR 334
Description: Mouse polyclonal to Tenascin C

Tenascin antibody
70R-14232 100 ug
EUR 322
Description: Affinity purified Mouse polyclonal Tenascin antibody

Tenascin antibody
70R-15292 100 ug
EUR 327
Description: Rabbit polyclonal Tenascin antibody

Tenascin antibody
10R-T103a 100 ug
EUR 476
Description: Mouse monoclonal Tenascin antibody

Tenascin antibody
10R-7904 100 ug
EUR 322
Description: Mouse monoclonal Tenascin antibody

Tenascin C (Stromal Marker For Epithelial Malignancy); Clone T2H5 (Concentrate)
RA0135-C.1 0.1 ml
EUR 125

Tenascin C (Stromal Marker For Epithelial Malignancy); Clone T2H5 (Concentrate)
RA0135-C.5 0.5 ml
EUR 247

Tenascin C (TNC) Antibody Pair
abx117625-1pair5x96wellplates 1 pair (5x96 well plates)
EUR 1010
  • Shipped within 5-10 working days.

Polyclonal Tenascin (TN-C) Antibody
APR13724G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Tenascin (TN-C) . This antibody is tested and proven to work in the following applications:

Tenascin-C Polyclonal Conjugated Antibody
C41914 100ul
EUR 397

Tenascin C (TNC) Antibody (Biotin)
20-abx272223
  • EUR 439.00
  • EUR 244.00
  • EUR 1261.00
  • EUR 606.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-15 working days.

Tenascin C (TNC) Antibody (Biotin)
20-abx273278
  • EUR 467.00
  • EUR 244.00
  • EUR 1344.00
  • EUR 634.00
  • EUR 356.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-15 working days.

Anti-Tenascin C/TNC Antibody
PA2055 100ug/vial
EUR 334

Tenascin C Blocking Peptide
20-abx061883
  • EUR 258.00
  • EUR 384.00
  • 1 mg
  • 5 mg
  • Shipped within 5-10 working days.

Tenascin C Blocking Peptide
20-abx062761
  • EUR 272.00
  • EUR 411.00
  • 1 mg
  • 5 mg
  • Shipped within 5-10 working days.

Recombinant human Tenascin-C
P1634 100ug Ask for price
  • Uniprot ID: Q99857
  • Reconstitution: Metal affinity chromatography on Fn Super Capacity Column (Nickel)
Description: Recombinant protein for human Tenascin-C

Recombinant Tenascin C (TNC)
4-RPB975Hu01
  • EUR 476.32
  • EUR 230.00
  • EUR 1511.20
  • EUR 570.40
  • EUR 1040.80
  • EUR 382.00
  • EUR 3628.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P24821
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 15.8kDa
  • Isoelectric Point: 5.7
Description: Recombinant Human Tenascin C expressed in: E.coli

Recombinant Tenascin C (TNC)
4-RPB975Mu01
  • EUR 485.28
  • EUR 233.00
  • EUR 1544.80
  • EUR 581.60
  • EUR 1063.20
  • EUR 388.00
  • EUR 3712.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: Q80YX1
  • Buffer composition: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 51.9kDa
  • Isoelectric Point: 4.6
Description: Recombinant Mouse Tenascin C expressed in: E.coli

Recombinant Tenascin C (TNC)
4-RPB975Ra01
  • EUR 503.20
  • EUR 238.00
  • EUR 1612.00
  • EUR 604.00
  • EUR 1108.00
  • EUR 400.00
  • EUR 3880.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: B2LYI9
  • Buffer composition: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 12.6kDa
  • Isoelectric Point: 5.1
Description: Recombinant Rat Tenascin C expressed in: E.coli

Recombinant Tenascin C (TNC)
4-RPB975Ra02
  • EUR 503.20
  • EUR 238.00
  • EUR 1612.00
  • EUR 604.00
  • EUR 1108.00
  • EUR 400.00
  • EUR 3880.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: B2LYI9
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 16.6kDa
  • Isoelectric Point: Inquire
Description: Recombinant Rat Tenascin C expressed in: E.coli

Recombinant Tenascin C (TNC)
4-RPB975Ra03
  • EUR 503.20
  • EUR 238.00
  • EUR 1612.00
  • EUR 604.00
  • EUR 1108.00
  • EUR 400.00
  • EUR 3880.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: B2LYI9
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 19.5kDa
  • Isoelectric Point: 4.3
Description: Recombinant Rat Tenascin C expressed in: E.coli

Anti-Tenascin C (3B4)
YF-MA13620 100 ug
EUR 363
Description: Mouse monoclonal to Tenascin C

Polyclonal TNC / Tenascin C Antibody (C-Terminus)
APR13764G 0.05ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TNC / Tenascin C (C-Terminus). This antibody is tested and proven to work in the following applications:

Tenascin C (TNC) Polyclonal Antibody (Human)
4-PAB975Hu01
  • EUR 239.00
  • EUR 2391.00
  • EUR 598.00
  • EUR 299.00
  • EUR 211.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: TNC (Val49~Lys181)
  • Buffer composition: 0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Description: A Rabbit polyclonal antibody against Human Tenascin C (TNC)

Tenascin C (TNC) Polyclonal Antibody (Mouse)
4-PAB975Mu01
  • EUR 243.00
  • EUR 2457.00
  • EUR 613.00
  • EUR 305.00
  • EUR 212.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: TNC (Cys174~Ser621)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Mouse Tenascin C (TNC)

Tenascin C (TNC) Polyclonal Antibody (Rat)
4-PAB975Ra01
  • EUR 251.00
  • EUR 2589.00
  • EUR 643.00
  • EUR 317.00
  • EUR 216.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: TNC (Asp513~Ser621)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Rat Tenascin C (TNC)

Tenascin C (TNC) Polyclonal Antibody (Rat)
4-PAB975Ra02
  • EUR 251.00
  • EUR 2589.00
  • EUR 643.00
  • EUR 317.00
  • EUR 216.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: TNC (Cys356~Asp495)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Rat Tenascin C (TNC)

Tenascin C (TNC) Polyclonal Antibody (Rat)
4-PAB975Ra03
  • EUR 251.00
  • EUR 2576.00
  • EUR 640.00
  • EUR 316.00
  • EUR 215.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: TNC (Val175~Gly342)
  • Buffer composition: PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Description: A Rabbit polyclonal antibody against Rat Tenascin C (TNC)

Tenascin C (TNC) Monoclonal Antibody (Human)
4-MAB975Hu22
  • EUR 247.00
  • EUR 2523.00
  • EUR 628.00
  • EUR 311.00
  • EUR 214.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
  • Sequence of the immunogen: Val49~Lys181
  • Buffer composition: 0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Description: A Mouse monoclonal antibody against Human Tenascin C (TNC)

Anti-Tenascin C Rabbit Monoclonal Antibody
M00936-1 100ug/vial
EUR 397
Description: Rabbit Monoclonal Tenascin C Antibody. Validated in WB and tested in Human.

Tenascin antibody (HRP)
60R-1711 100 ug
EUR 327
Description: Rabbit polyclonal Tenascin antibody (HRP)

Tenascin antibody (FITC)
60R-1712 100 ug
EUR 327
Description: Rabbit polyclonal Tenascin antibody (FITC)

Tenascin antibody (biotin)
60R-1713 100 ug
EUR 327
Description: Rabbit polyclonal Tenascin antibody (biotin)

Tenascin Antibody (Biotin)
20-abx105965
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin Antibody (Biotin)
20-abx105966
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin Antibody (FITC)
20-abx107380
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin Antibody (FITC)
20-abx107381
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin Antibody (HRP)
20-abx108800
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin Antibody (HRP)
20-abx108801
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin (TNC) Antibody
20-abx110255
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin (TNC) Antibody
20-abx110256
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Tenascin (TNC) Antibody
abx140268-01mg 0.1 mg
EUR 384
  • Shipped within 5-12 working days.

Tenascin-X Antibody
abx238596-100ug 100 ug
EUR 509
  • Shipped within 5-12 working days.

Tenascin(T2H5) Antibody
BNUB0392-100 100uL
EUR 209
Description: Primary antibody against Tenascin(T2H5), Concentration: 0.2mg/mL

Tenascin(T2H5) Antibody
BNUB0392-500 500uL
EUR 458
Description: Primary antibody against Tenascin(T2H5), Concentration: 0.2mg/mL

Tenascin(T2H5) Antibody
BNUM0392-50 50uL
EUR 395
Description: Primary antibody against Tenascin(T2H5), 1mg/mL

Tenascin(T2H5) Antibody
BNC040392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF405S conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC040392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF405S conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC610392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF660R conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC610392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF660R conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC470392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF647 conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC470392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF647 conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC550392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF555 conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC550392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF555 conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC050392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF405M conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC050392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF405M conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC400392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF640R conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC400392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF640R conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC430392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF543 conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC430392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF543 conjugate, Concentration: 0.1mg/mL

Tenascin (TNC) Antibody
abx411626-02mg 0.2 mg
EUR 565
  • Shipped within 1 week.

Tenascin(T2H5) Antibody
BNC800392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF680 conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC800392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF680 conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC810392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), CF680R conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNC810392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), CF680R conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNCP0392-250 250uL
EUR 383
Description: Primary antibody against Tenascin(T2H5), PerCP conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNCR0392-250 250uL
EUR 383
Description: Primary antibody against Tenascin(T2H5), RPE conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNCA0392-250 250uL
EUR 383
Description: Primary antibody against Tenascin(T2H5), APC conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNCAP0392-100 100uL
EUR 199
Description: Primary antibody against Tenascin(T2H5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Tenascin(T2H5) Antibody
BNCAP0392-500 500uL
EUR 544
Description: Primary antibody against Tenascin(T2H5), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL
The Fgpal1 mutant was regular in meiosis with eight nuclei in creating asci however most asci have been aborted. Taken collectively, our outcomes confirmed that FgPal1 performs a function in sustaining polarized tip progress and coordination between nuclear division and cytokinesis, and additionally it is vital for infectious progress and developments of ascospores by the free cell formation course of. This article is protected by copyright. All rights reserved.

New response evaluation criteria in solid tumours: revised RECIST guideline

BACKGROUNDAssessment of the change in tumour burden is a vital characteristic of the <em>medical</em> evaluation of most cancers therapeutics: each tumour shrinkage (goal response) and illness development are helpful endpoints in trials.

Since RECIST was revealed in 2000, many <em>investigators</em>, cooperative teams, business and authorities authorities have adopted these criteria in the evaluation of remedy outcomes. However, quite a lot of questions and points have arisen which have led to the event of a revised RECIST guideline (model 1.1).

Evidence for adjustments, summarised in separate papers in this particular problem, has come from evaluation of a giant information warehouse >>6500 sufferers), simulation research and literature evaluations. HIGHLIGHTS OF REVISED RECIST 1.1: Major adjustments embrace:

Number of lesions to be assessed: based mostly on proof from quite a few trial databases merged into an information warehouse for evaluation functions, the variety of lesions required to evaluate tumour burden for response dedication has been lowered from a most of 10 to a most of 5 complete (and from 5 to 2 per organ, most).

Assessment of pathological lymph nodes is now integrated: nodes with a brief axis of 15 mm are thought-about measurable and assessable as goal lesions. The quick axis measurement needs to be included in the sum of lesions in calculation of tumour response.

New response evaluation criteria in solid tumours: revised RECIST guideline
New response evaluation criteria in solid tumours: revised RECIST guideline

Nodes that shrink to <10mm quick axis are thought-about regular. Confirmation of response is required for trials with response main endpoint however is now not required in randomised research for the reason that management arm serves as acceptable technique of interpretation of knowledge.

Disease development is clarified in a number of points: in addition to the earlier definition of development in goal illness of 20% enhance in sum, a 5mm absolute enhance is now required as effectively to protect towards over calling PD when the entire sum may be very small.

Furthermore, there’s steerage provided on what constitutes ‘unequivocal development’ of non-measurable/non-target illness, a supply of confusion in the unique RECIST guideline. , a piece on detection of latest lesions, together with the interpretation of FDG-PET scan evaluation is included. Imaging steerage: the revised RECIST features a new imaging appendix with up to date suggestions on the optimum anatomical evaluation of lesions.

CONCLUSIONSA

key query thought-about by the RECIST Working Group in growing RECIST 1.1 was whether or not it was acceptable to maneuver from anatomic unidimensional evaluation of tumour burden to both volumetric anatomical evaluation or to purposeful evaluation with PET or MRI. It was concluded that, at current, there’s not adequate standardisation or proof to desert anatomical evaluation of tumour burden. The solely exception to that is in the usage of FDG-PET imaging as an adjunct to dedication of development. As is detailed in the ultimate paper in this particular problem, the usage of these promising newer approaches requires acceptable medical validation research.

The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the duty of revising the 1984 criteria for Alzheimer’s illness (AD) dementia.

The workgroup sought to make sure that the revised criteria can be versatile sufficient for use by each basic healthcare suppliers with out entry to neuropsychological testing, superior imaging, and cerebrospinal fluid measures, and specialised investigators concerned in analysis or in medical trial research who would have these instruments out there.

We current criteria for all-cause dementia and for AD dementia. We retained the final framework of possible AD dementia from the 1984 criteria. On the premise of the previous 27 years of expertise, we made a number of adjustments in the medical criteria for the prognosis. We additionally retained the time period doable AD dementia, however redefined it in a way extra centered than earlier than.

Biomarker proof was additionally built-in into the diagnostic formulations for possible and doable AD dementia to be used in analysis settings. The core medical criteria for AD dementia will proceed to be the cornerstone of the prognosis in medical follow, however biomarker proof is anticipated to reinforce the pathophysiological specificity of the prognosis of AD dementia.

Much work lies forward for validating the biomarker prognosis of AD dementia.

The prognosis of dementia as a consequence of Alzheimer’s illness: suggestions from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic pointers for Alzheimer’s illness

The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the duty of revising the 1984 criteria for Alzheimer’s illness (AD) dementia.

The workgroup sought to make sure that the revised criteria can be versatile sufficient for use by each basic healthcare suppliers with out entry to neuropsychological testing, superior imaging, and cerebrospinal fluid measures, and specialised investigators concerned in analysis or in medical trial research who would have these instruments out there. We current criteria for all-cause dementia and for AD dementia.

We retained the final framework of possible AD dementia from the 1984 criteria. On the premise of the previous 27 years of expertise, we made a number of adjustments in the medical criteria for the prognosis.

We additionally retained the time period doable AD dementia, however redefined it in a way extra centered than earlier than. Biomarker proof was additionally built-in into the diagnostic formulations for possible and doable AD dementia to be used in analysis settings.

The core medical criteria for AD dementia will proceed to be the cornerstone of the prognosis in medical follow, however biomarker proof is anticipated to reinforce the pathophysiological specificity of the prognosis of AD dementia. Much work lies forward for validating the biomarker prognosis of AD dementia.

OBJECTIVEThe etiology of ischemic stroke impacts prognosis, end result, and administration. Trials of therapies for sufferers with acute stroke ought to embrace measurements of responses as influenced by subtype of ischemic stroke.

A system for categorization of subtypes of ischemic stroke primarily based mostly on etiology has been developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST).METHODSA classification of subtypes was ready utilizing medical options and the outcomes of ancillary diagnostic research.

“Possible” and “possible” diagnoses may be made based mostly on the doctor’s certainty of prognosis. The usefulness and interrater settlement of the classification had been examined by two neurologists who had not participated in the writing of the criteria. The neurologists independently used the TOAST classification system in their bedside evaluation of 20 sufferers, first based mostly solely on medical options after which after reviewing the outcomes of diagnostic assessments.

RESULTSThe TOAST classification denotes 5 subtypes of ischemic stroke: 1) large-artery atherosclerosis, 2) cardioembolism, 3) small-vessel occlusion, 4) stroke of different decided etiology, and 5) stroke of undetermined etiology. Using this ranking system, interphysician settlement was very excessive.

The two physicians disagreed in just one affected person. They had been each capable of attain a selected etiologic prognosis in 11 sufferers, whereas the reason for stroke was not decided in 9.CONCLUSIONSThe TOAST stroke subtype classification system is straightforward to make use of and has good interobserver settlement.

This system ought to permit investigators to report responses to remedy amongst essential subgroups of sufferers with ischemic stroke. Clinical trials testing therapies for acute ischemic stroke ought to embrace comparable strategies to diagnose subtypes of stroke.

BACKGROUNDA

cute kidney damage (AKI) is a fancy dysfunction for which presently there isn’t a accepted definition. Having a uniform normal for diagnosing and classifying AKI would improve our means to handle these sufferers.

Future medical and translational analysis in AKI would require collaborative networks of investigators drawn from varied disciplines, dissemination of knowledge by way of multidisciplinary joint conferences and publications, and improved translation of data from pre-medical analysis. We describe an initiative to develop uniform requirements for outlining and classifying AKI and to ascertain a discussion board for multidisciplinary interplay to enhance take care of sufferers with or in danger for AKI.

METHODS

Members representing key societies in crucial care and nephrology together with extra consultants in grownup and pediatric AKI participated in a two day convention in Amsterdam, The Netherlands, in September 2005 and had been assigned to one among three workgroups. Each group’s discussions fashioned the premise for draft suggestions that had been later refined and improved throughout dialogue with the bigger group.

Dissenting opinions had been additionally famous. The closing draft suggestions had been circulated to all contributors and subsequently agreed upon because the consensus suggestions for this report. Participating societies endorsed the suggestions and agreed to assist disseminate the outcomes.

RESULTSThe time period AKI is proposed to signify the complete spectrum of acute renal failure. Diagnostic criteria for AKI are proposed based mostly on acute alterations in serum creatinine or urine output.

A staging system for AKI which displays quantitative adjustments in serum creatinine and urine output has been developed.CONCLUSIONSWe describe the formation of a multidisciplinary collaborative community centered on AKI. We have proposed uniform requirements for diagnosing and classifying AKI which can have to be validated in future research. The Acute Kidney Injury Network affords a mechanism for continuing with efforts to enhance affected person outcomes.